A retrospective multicenter study was performed to assess the clinical results in patients with acquired aplastic anemia (AA) allografted over a 19 year period and to identify prognostic factors influencing survival. From April 1978 to December 1997, 176 patients were transplanted. Records from 160 receiving related matched bone marrow transplantation (BMT) were reviewed. Fifty-two percent of the patients were older than 20 years, 5% older than 40; 6.3% were untransfused at BMT and 56.2% had received prior treatments. Conditioning regimens were with chemotherapy in 43.7% of the procedures and with additional irradiation in 56.3%. Graft-versus-host disease (GVHD) prophylaxis was based on cyclosporin A (CsA) in 58.1% of the patients while methotrexate (MTX) was administered to 41.9%. Transplantation earlier on, a longer interval from diagnosis to BMT, GVHD prophylaxis with MTX, graft failure/rejection and acute severe GVHD were adverse factors for survival. The use of CsA emerged as the main factor for the improvement, inducing a significant decrease in graft failure/rejection rate and severe acute GVHD when compared with MTX alone. Radiation-containing regimens decreased the graft failure/rejection rate without improving survival due to the increased risk of acute GVHD. Age and number of transfusions pretransplant did not influence outcome. Survival achieved since 1991 is 79.79%, and graft fail- 
Register-based retrospective studies have contributed to tailoring different treatment strategies in patients with aplastic anemia (AA). [1] [2] [3] [4] Apart from the series by the Seattle 5 and Paris 6 groups, single center [7] [8] [9] [10] [11] [12] and controlled studies [13] [14] [15] are few and often include small populations, due to the low incidence of the disease. Registers, although introducing more biases, allow treatment options to be compared with fairly good reliability of results. During 1997, the Spanish Working Party Group for AA decided to compile its experience with bone marrow transplantation (BMT) in order to identify the risk factors for treatment failure and to make possible the generation of new therapeutic guidelines to minimize diversity of indications and therefore improve treatment results. A survey collected previously from 57 Spanish hematology departments had revealed that 80% offered BMT as the first treatment option to patients with SAA and a fully matched sibling donor, although 86% of them used local protocols with different transplant procedures and with a wide age range of eleg-ibility criteria. Here, we report the outcome of 160 patients with acquired AA communicated to the register and transplanted over a 19 year period.
Patients and methods

Patients
One hundred and seventy-six patients with acquired AA allografted between April 1978 and December 1997 in 11 hospitals were reported to the Spanish Group of Hematopoietic Transplantation. Sixteen patients were excluded for this analysis including unrelated (4), mismatched family (2), syngeneic (3), fetal liver (1), and peripheral blood stem cell (5) transplants or for lack of essential data (1) .
Patients, disease characteristics and transplant procedures are summarized in Table 1 . Only eight (5%) out of 160 patients were older than 40 years and seven of them underwent transplantation after failing immunosuppressive treatment. Disease severity was defined according to the International AA Study Group. 16 Eleven (6.9%) patients with non-severe AA at diagnosis were transplanted when the disease became more severe. Only 6.3% of the patients were untransfused at transplantation, and 56.2% had received other treatments before BMT. Conditioning regimens and graft-versus-host (GVHD) prophylaxis used were diverse. High-dose cyclosphosphamide (Cy) alone (52 patients) or combined with antithymocyte globulin and/or procarbazine (18 patients) 11, 17 was used in 43.7% of the procedures and along with irradiation in 56.3%. Irradiation was administered as TBI, 7 (3 Gy) in 11% of the procedures and as TLI 10, 18 (6-7.5 Gy) or TAI 6 (6 Gy) in 60% and 29% of the procedures, respectively. GVHD prophylaxis was with cyclosporin A (CsA) alone (14 patients) 19 or combined with short-term MTX (79 patients) 13 in 58.1% of the patients, while MTX alone 13 (60 patients) or combined with antithymocyte globulin 18 (seven patients) was administered in 41.9% of the cases. Recipient and donor were sex mismatched in 46.9% of the transplants. Only two out of 67 female donors had had prior pregnancies (data on 154 donors) and none of 151 donors analyzed had been transfused before harvest.
Methods
Survival and associated variables
Survival was considered from the date of BMT until death, whatever the cause, or last follow-up. To identify the effects of patient, donor, disease and treatment-related factors on survival, univariate analyses were performed with the Kaplan-Meier product limit method, 20 and differences between survivals were evaluated using the log rank test. Variables included in the analysis are those listed in Table  1 with the exception of CMV status, unknown in 35.26% of the patients. Variables with P values lower than 0.10 were entered into a Cox regression model in order to ascertain their independent effect on survival and their respective hazard ratios. 
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Study of variables associated with graft failure and acute severe grade GVHD
We studied any possible association between each independent and dependent variable. For qualitative variables a 2 test was used, while a Mann-Whitney U test was employed for quantitative variables. Confidence intervals for the proportions were calculated by means of a binomial distribution. Thereafter, confusion and effect modification were tested by mean of a Mantel-Haenzel stratified analysis. Homogeneity among strata was calculated using the Welch test and stratified relative risks 22, 23 with the method of Robins-Greenland-Breslow.
All P values reported are two-sided and statistical significance was considered for a P value of less than 0.05. Statistical analyses were performed with CIA (BMJ, 1989), V 1. 
Results
Engraftment, graft failure, GVHD and cause of death
Twelve (7.5%) patients died before day +21 and were therefore not evaluable for engraftment. Eight patients (5%) suffered primary graft failure and 16 (10.0%) secondary graft failure. One hundred and twenty four-patients achieved sustained hematological reconstitution. Fifty-two (36.1%) out of 144 patients at risk developed acute grade II-IV GVHD, 28 grade III-IV (19.4%). Thirty (23.8%) out of 126 who survived more than 100 days developed chronic GVHD, 10 (7.9%) extensive disease.
Sixty patients died due to the following reasons: acute GVHD (19 patients; 31.1%), infection (15; 25%), graft failure (12; 20%), hemorrhage (7; 11.6%), chronic GVHD (4; 6.6%), cardiac toxicity (2; 3.3%) and VOD (1; 1.7%). Interstitial pneumonia was recorded at the time of death in 11 patients, four due to CMV. Pneumonitis was associated with active acute or chronic GVHD in seven patients, with graft failure and sepsis in two and as an isolated event in two patients. Median survival of patients with primary graft failure was 38.5 days (range 22 to 98 days), and only one patient underwent a second BMT, without success. Secondary graft failures were observed at a median time of 5.6 months (range 1.6 to 38 months). Six out of 16 patients received second marrow grafts, and one received immunosuppressive therapy. Three of them became long-term survivors. Among the other nine patients, co-morbidities were present in six when they lost their grafts: one lung aspergillosis, three acute GVHD and two extensive chronic GVHD. With a median follow-up of 7.6 years (range 0.11-19.03 years), 100 patients (62.5%) were alive with a median Karnofsky performance status of 100% (range 50-100%). Two out of 155 patients with follow-ups of more than 1 year developed a malignancy. Neither had received irradiation as part of conditioning or developed chronic GVHD. A male, who was a heavy smoker and drug consumer, developed a squamous cell carcinoma of the lip 11.5 years post transplant, and a female patient developed an in situ carcinoma of the cervix 3.3 years post transplant. Both patients are alive after appropiate treatment.
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Variables associated with survival
We looked for any association of characteristics depending on recipient, donor, transplant procedure and post-transplant events with overall survival. The results of the multivariate analysis are shown in Table 2 . The period in which BMTs were performed, interval from diagnosis to BMT, type of GVHD prophylaxis (with or without CsA), acute grade III-IV GVHD and graft failure were the variables significantly associated with outcome.
Kaplan-Meier survival curves according to the time of transplantation are shown in Figure 1 . Projected survival increased successively over the four periods considered: 25.88% before 1980; 47.52% in the period 1981-1985; 68.18% during 1986-1990 and 79.79% since 1991 (P = 0.0001). Patients who received GVHD prophylaxis based on CsA had significantly better survivals than did patients receiving MTX (72.95 Ϯ 0.61% vs 46.87 Ϯ 0.46%, P = 0.0012). Graft failure and severe acute GVHD were the other variables significantly associated with final outcome. Survival for patients without graft failure was 77.27 Ϯ 0.37% vs 0% and 16.67 Ϯ 9% for patients with primary and secondary graft failure, respectively (P = 0.00001). Survival for patients with no, or moderate acute GVHD was 77.26 Ϯ 3% vs 32.14 Ϯ 8% for patients with grade III-IV GVHD (P = 0.0001).
Relationship between patient, disease, transplant procedure and events within the period of transplantation
Some patient characteristics and transplant procedures changed with time. The association of important variables with the period of transplantation is shown in Table 3 . Mean recipient and donor ages were progressively higher as were patients previously untreated at transplant. Also, numbers of patients with active hemorrhage at transplant were higher in the last period analyzed. Regarding transplant conditioning, regimens with radiotherapy were more frequently used during the 1980s, with a decline since 1991. There were also significant changes in GVHD prophylaxis, those based on CsA being progressively incorporated. Regarding post-transplant events, graft failure decreased significantly over time with a rate of 6.0% in the most recent period. The overall incidence of grades II-IV acute GVHD did not change (P = 0.218), but a trend towards a decrease in grades III-IV was observed (P = 0.051) over time. Distribution of the remaining variables considered in the analysis (sex, etiology, severity, number of prior transfusions, prior infection, donor-recipient sex match, ABO match, interval from diagnosis to BMT and chronic GVHD) did not show significant changes during the study period. Table 3 Relationship between year of BMT and patient, disease and treatment characteristics 
Variables associated with graft failure and acute GVHD
The results are summarized in Table 4 . Graft failure rates declined progressively with time (60%, 20.9%, 7.5% and 6%, P = 0.001), and were significantly lower with conditioning regimens containing radiotherapy (7.2% vs 27.7%, P = 0.001), and with CsA-based GVHD prophylaxis (8% vs 27.9%, P = 0.001). Recipient age and donorrecipient sex match showed a marginal association with graft failure (P = 0.07). Considering acute grade II-IV GVHD, a significantly higher incidence was associated with radiation containing conditioning regimens (45.1% vs 24.2%, P = 0.007) (data not shown in Table 4 ) although such an association did not reach statistical significance for grades III-IV GVHD (24.4% vs 12.9%, P = 0.094). CsA-based GVHD prophylaxis did not influence the incidence of acute grades II-IV GVHD, but a significantly lower proportion of patients receiving CsA developed grades III-IV GVHD when compared to those receiving MTX (12.6% vs 29.8%, P = 0.017). We observed no associations regarding quantitative variables such as recipient and donor mean ages, interval from diagnosis to BMT (in days), number of prior transfusions or number of cells infused with the risks of graft failure and acute grades III-IV GVHD (data not shown but available). As conditioning and GVHD prophylaxis influenced incidence of graft failure and acute GVHD, we studied the effects of each of these factors on the other. Results are shown in Table 5 . Radiation containing regimens and CsAbased GVHD prophylaxis significantly decreased graft failure rates, with relative risks of 0.78 (CI: 0.67-0.92) and 0.81 (CI: 0.71-0.94), respectively. Regarding GVHD, the administration of CsA was significantly associated with a lower incidence of grades III-IV GVHD, with a relative risk of 0.80 (CI: 0.66-0.96) while an increased risk was apparent for radiation containing regimens, with a relative risk of 1.15 (CI: 0.99-1.34), although this did not reach statistical significance.
209 Table 4 Analysis of qualitative variables associated with the incidence of graft failure and grades III-IV acute GVHD 
Discussion
The outcome of patients transplanted for AA has improved significantly with time. 3, 4, 24 In this series, the projected long-term survival is 80% since 1991. The period of transplant emerged as an independent factor for survival in spite of being associated with the other variables associated with outcome, namely the introduction of CsA-based prophylaxis for GVHD, and a progressive decrease in graft failure and severe acute GVHD rates with time.
When the effect of time was adjusted for the other variables influencing survival, the most striking difference was detected since 1985, when CsA (associated with short-term MTX in 84.9% of patients) replaced MTX alone for GVHD prophylaxis, a finding consistent with previous reports. 2, 3, 13 The benefit of CsA on survival has been attributed to different reasons, depending on the series. In this cohort of patients, CsA significantly decreased graft failure rates and severe acute GVHD. CsA did not decrease graft failure
Bone Marrow Transplantation
Table 5A
Estimation of the effects of conditioning regimen and GVHD prophylaxis in the incidence of graft failure and grades III-IV GVHD. Proportion of patients with graft failure according to conditioning with or without irradiation and post-grafting immunosuppression with or without CsA
Radiation
No radiation 
Table 5B
Estimation of the effects of conditioning regimen and GVHD prophylaxis in the incidence of graft failure and grades III-IV GVHD. Proportion of patients with grades III-IV GVHD according to conditioning with or without irradiation and post-grafting immunosuppression with or without CsA
Radiation
No radiation rates when compared to MTX in the only randomized trial performed in AA comparing both types of prophylaxis, 13, 14 but such an association has been observed in other studies. 25, 26 The effect of CsA on reduction of severe acute GVHD is consistent with previous reports. 13, 14, 27 CsAbased prophylaxis retained significance on multivariate analysis in spite of being strongly associated with a decrease in graft failure and severe GVHD. Additional deaths due to bacterial and fungal infections and hemorrhage in patients receiving MTX were probably the reasons for the advantage in using CsA, although the numbers were too small to observe a statistical significance. Regardless of CsA treatment, further improvement in survival with time was detected in this study. Probably, all these factors, together with improved supportive care and management of complications account for the observed improvement.
Graft failure/rejection and acute GVHD remained important factors influencing outcome. Survival of patients with graft failure/rejection was disappointing even though 43.7% of patients had received second treatments. Sixteen percent survival for late graft failure differed from the 43% reported by the European Bone Marrow Transplantation registry (EBMTR), whereas in our series survival of patients without rejection reached 77%, higher than the survival communicated in that study. 26 Period of transplant, conditioning with radiation and CsA-based GVHD prophylaxis were associated with a decrease in graft failure/rejection rate. Radiation containing regimens significantly decreased graft failure rates, even adjusting the results for GVHD prophylaxis. However, this benefit did not result in improved survival due to the increased risk of acute GVHD, a finding consistent with results previously communicated by the International Bone Marrow Transplant Registry. 2 In addition, graft failure declined with time, with a rate of 6% since 1991, in spite of a lower proportion of irradiated patients in the last period. Accordingly, reports of patients transplanted in more recent years have noted graft failure/rejection rates of 4-8% with non-radiation containing regimens, even in multiply transfused patients. 15, 28 Radiation containing regimens and treatment of chronic GVHD with azathioprine have been associated with a significantly increased risk of developing solid tumors in patients with AA. 29 Of note, with a median follow-up for survivors of 7.6 years in this study, neither of the two patients who developed a solid tumor had been exposed to these risk factors.
Acute grades II-IV GVHD incidence was unchanged over time and similar incidences were observed in patients receiving MTX or CsA-based prophylaxis. However, the incidence of acute grades III-IV GVHD decreased with time and was associated with CsA use. This finding is consistent with previous reports. 4, 13, 14, 27 We observed no differences in most of the patient and disease characteristics over time, with the exception of a progressively higher recipient and donor age and a significantly higher proportion of previously untreated patients at transplant over recent years. The well known adverse effect of age on survival [2] [3] [4] [5] seems to have been overcome with time, as age did not affect survival in this study. As in other registers, the proportion of patients older than 40 years is low but younger patients were also transplanted in the earlier periods, with significantly worse outcomes. The EBMT, however, communicated that age remained significantly associated with survival, although outcome improved significantly within all the age groups over time. 5 Similarly, we observed no adverse influence of the number of prior transfusions on survival. 2, 3, 5 Of note, the number of prior transfusions remained stable through the periods analyzed, probably indicating the difficulty in maintaining a stringent transfusion policy in AA patients. Accordingly, it has been recognized than less than 15% of AA patients can remain untransfused at transplant. 30 Interestingly, in our study the number of patients with active hemorrhage apparently increased during the latest period, but whether this might reflect more optimized transfusion support in these patients is unknown.
In summary, a long-term survival of 80% can be safely offered today to patients with acquired AA, up to 40 years of age. CsA-based post-graft immunosuppression was the main factor responsible for improving outcome, while radiation in the conditioning regimen, age and the number of prior transfusions did not have an effect on survival. Better management of graft failure and new strategies for reducing GVHD seem crucial to achieving optimal results.
